

Special Issue

Palliative Radiotherapy for Cancer

Message from the Guest Editor

Radiation therapy has long been used for palliation in cancer. Traditionally, clinical practice has focused on the relief of symptoms while causing the fewest side effects and most minimal treatment burden. In modern practice, sophisticated treatment techniques such as VMAT, SBRT, SFRT are no longer restricted to the care of patients with curable cancers. Novel applications of radiotherapy that can influence the trajectory of metastatic processes and, hence, the patients' cancer journey and quality of life are increasingly being investigated. The rapid growth of radiotheranostics provides us with another exciting tool that is capable of both relieving symptoms and changing the clinical course of metastatic disease. In this Special Issue, we welcome original research articles, high-quality systematic reviews and meta-analyses that will expand our understanding of how radiation therapy can improve the journeys of cancer patients and reduce their symptom burden in both the short and long term, with a strong focus on patient reported outcomes. Translational work that will support clinical studies in this field is also welcome.

Guest Editor

Prof. Rebecca Wong

Radiation Medicine Program, Princess Margaret Cancer Centre,
Toronto, ON M5G 2M9, Canada

Deadline for manuscript submissions

30 December 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/227155

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)